EMA Authorised: Korjuny (catumaxomab) — Atnahs Pharma Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Korjuny (catumaxomab) by Atnahs Pharma Netherlands B.V. for the treatment of malignant ascites.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• Korjuny (catumaxomab)

Snippet

Status: Authorised. Therapeutic area: Ascites. MAH: Atnahs Pharma Netherlands B.V.. Decision date: 23/09/2025